Galnon: Difference between revisions

{{drugbox |

| IUPAC_name = 9H-​fluoren-​9-​ylmethyl N-​[(2S)-​1-​([(2S)-​6-​amino-​1-​[(4-​methyl-​2-​oxochromen-​7-​ yl)amino]-​1-​oxohexan-​2-​yl]amino)-​3-cyclohexyl-​1-​oxopropan-​2-​yl]carbamate

| image = Galnon_structure.png

| width = 200

| CAS_number = 475115-35-6

| ATC_prefix =

| ATC_suffix =

| PubChem = 5311268

| DrugBank =

| C=40 | H=46 | N=4 | O=6

| molecular_weight = 678.815

| smiles = Cc3cc(=O)oc6cc(ccc36)NC(=O)C(CCCCN)NC(=O)C(CC5CCCCC5)NC(=O)OCC1c2ccccc2-c4c1cccc4

| bioavailability =

| protein_bound =

| metabolism =

| excretion =

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category=

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->

| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

}}

'''Galnon''' is a drug which acts as a selective, non-peptide [[agonist]] at the [[galanin]] [[Receptor (biochemistry)|receptor]]s [[Galanin receptor|GAL_R]].<ref name="pmid12011470">{{cite journal |author=Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hökfelt T, Wasterlain C, Bartfai T, Langel U |title=Anticonvulsant activity of a nonpeptide galanin receptor agonist |journal=Proceedings of the National Academy of Sciences of the United States of America |volume=99 |issue=10 |pages=7136–41 |year=2002 |month=May |pmid=12011470 |pmc=124541 |doi=10.1073/pnas.102163499 |url=}}</ref><ref name="pmid15944006">{{cite journal |author=Sollenberg U, Bartfai T, Langel U |title=Galnon--a low-molecular weight ligand of the galanin receptors |journal=Neuropeptides |volume=39 |issue=3 |pages=161–3 |year=2005 |month=June |pmid=15944006 |doi=10.1016/j.npep.2004.12.019 |url=}}</ref> It has [[anticonvulsant]], [[anxiolytic]], [[anorectic]] and [[amnestic]] effects in animal studies.<ref name="pmid15003717">{{cite journal |author=Abramov U, Florén A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U |title=Regulation of feeding by galnon |journal=Neuropeptides |volume=38 |issue=1 |pages=55–61 |year=2004 |month=February |pmid=15003717 |doi=10.1016/j.npep.2004.01.001 |url=}}</ref><ref name="pmid15944018">{{cite journal |author=Badie-Mahdavi H, Behrens MM, Rebek J, Bartfai T |title=Effect of galnon on induction of long-term potentiation in dentate gyrus of C57BL/6 mice |journal=Neuropeptides |volume=39 |issue=3 |pages=249–51 |year=2005 |month=June |pmid=15944018 |doi=10.1016/j.npep.2004.12.010 |url=}}</ref><ref name="pmid17637475">{{cite journal |author=Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE |title=Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon |journal=Neuropeptides |volume=41 |issue=5 |pages=307–20 |year=2007 |month=October |pmid=17637475 |doi=10.1016/j.npep.2007.05.001 |url=}}</ref><ref name="pmid19095221">{{cite journal |author=Kozlovsky N, Matar MA, Kaplan Z, Zohar J, Cohen H |title=The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder |journal=Biological Psychiatry |volume=65 |issue=5 |pages=383–91 |year=2009 |month=March |pmid=19095221 |doi=10.1016/j.biopsych.2008.10.034 |url=}}</ref><ref name="pmid19099295">{{cite journal |author=Narasimhaiah R, Kamens HM, Picciotto MR |title=Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice |journal=Psychopharmacology |volume=204 |issue=1 |pages=95–102 |year=2009 |month=May |pmid=19099295 |pmc=2872184 |doi=10.1007/s00213-008-1438-7 |url=}}</ref>

{{Neuropeptide agonists and antagonists}}

{{pharm-stub}}